BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260428T130000
DTEND;TZID=America/New_York:20260428T143000
DTSTAMP:20260417T062843
CREATED:20260402T204928Z
LAST-MODIFIED:20260415T153438Z
UID:2971-1777381200-1777386600@lifescievents.com
SUMMARY:Alterity Therapeutics Virtual KOL Event to Review and Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
DESCRIPTION:Join Alterity Therapeutics for a virtual key opinion leader (KOL) event featuring Roy Freeman\, MD (Harvard Medical School\, Beth Israel Deaconess Medical Center) and Daniel Claassen\, MD\, MS (Vanderbilt University Medical Center)\, alongside David Stamler\, MD\, (CEO\, Alterity Therapeutics)\, to discuss the significant unmet need and current treatment landscape in Multiple System Atrophy (MSA)\, a rare\, rapidly progressive neurodegenerative disease with no approved treatment\, and the opportunity for ATH434\, a novel\, potential first-in-class investigational agent in late-stage clinical development. \nPreviously presented Phase 2 data demonstrated up to 48% slowing of disease progression versus placebo with a favorable safety profile. \nEvent Highlights to Include: \n\nATH434 Overview: Alterity’s lead candidate and a potential first-in-class\, disease-modifying therapy for MSA\nMSA Background: Disease overview and review of therapeutic options\nPhase 2 Program: Review Phase 2 data\, including new insights and analyses\nPhase 3 Planning: High level overview of the planned Phase 3 program\n\nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/f91gsn7/.
URL:https://lifescievents.com/event/f91gsn7/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/Alterity-Banner.png
END:VEVENT
END:VCALENDAR